Home / Therapeutic Area / Swine and Avian Influenza Drug Development Pipeline Review, 2017

Swine and Avian Influenza Drug Development Pipeline Review, 2017

Published: Nov 2017 | Published By: GBI Research

Description

This report provides an overview of the Swine and Avian Influenza pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for influenza A virus, subtypes H5N1 and H1N1, and features dormant and discontinued projects.

H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. There are a total of 63 products in development for this indication, by 47 companies and six academic institutions.

H1N1 Infection also called as swine flu is a new kind of flu in humans. It's caused by the contagious H1N1 influenza virus. There are a total of 99 products in development for this indication, by 67 companies and 14 academic institutions.

In both types of influenza, the most common molecular target being studied is hemagglutinin, by a considerable margin. However, a number of both human and viral proteins are also under active development.

Scope

  • Which companies are the most active within each pipeline?
  • Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
  • To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
  • What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons To Buy

  • Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
  • Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
  • Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
  • Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Executive Summary

3 Introduction
3.1 Swine and Avian Influenza Report Coverage
3.2 Influenza A Virus, H5N1 Subtype Infections – Overview
3.3 Influenza A Virus, H1N1 Subtype Infections – Overview
3.4 GBI Research Report Guidance

4 Therapeutics Development
4.1 Influenza A Virus, H5N1 Subtype Infections
4.1.1 Pipeline Overview
4.1.2 Pipeline by Companies
4.1.3 Pipeline by Universities/Institutes
4.1.4 Products under Development by Companies
4.1.5 Products under Development by Universities/Institutes
4.2 Influenza A Virus, H1N1 Subtype Infections
4.2.1 Pipeline Overview
4.2.2 Pipeline by Companies
4.2.3 Pipeline by Universities/Institutes
4.2.4 Products under Development by Companies
4.2.5 Products under Development by Universities/Institutes

5 Therapeutics Assessment
5.1 Influenza A Virus, H5N1 Subtype Infections
5.1.1 Assessment by Target
5.1.2 Assessment by Mechanism of Action
5.1.3 Assessment by Route of Administration
5.1.4 Assessment by Molecule Type
5.2 Influenza A Virus, H1N1 Subtype Infections
5.2.1 Assessment by Target
5.2.2 Assessment by Mechanism of Action
5.2.3 Assessment by Route of Administration
5.2.4 Assessment by Molecule Type

6 Companies Involved in Therapeutics Development
6.1 Influenza A Virus, H5N1 Subtype Infections
6.1.1 Akshaya Bio Inc
6.1.2 Altimmune Inc
6.1.3 Antigen Express Inc
6.1.4 Aphios Corp
6.1.5 BiondVax Pharmaceuticals Ltd
6.1.6 CEL-SCI Corp
6.1.7 Cocrystal Pharma Inc
6.1.8 Curevac AG
6.1.9 Gemmus Pharma Inc
6.1.10 GlaxoSmithKline Plc
6.1.11 Hemispherx Biopharma Inc
6.1.12 iBio Inc
6.1.13 Inovio Pharmaceuticals Inc
6.1.14 Johnson & Johnson
6.1.15 Kineta Inc
6.1.16 Lakewood-Amedex Inc
6.1.17 Medicago Inc
6.1.18 Medigen Vaccine Biologics Corp
6.1.19 Microbiotix Inc
6.1.20 NanoBio Corp
6.1.21 Nanotherapeutics Inc
6.1.22 NanoViricides Inc
6.1.23 OPKO Health Inc
6.1.24 PaxVax Inc
6.1.25 PeptiDream Inc
6.1.26 Shionogi & Co Ltd
6.1.27 Takeda Pharmaceutical Company Ltd
6.1.28 TechnoVax Inc
6.1.29 Vaxart Inc
6.1.30 Vaxine Pty Ltd
6.1.31 Visterra Inc
6.2 Influenza A Virus, H1N1 Subtype Infections
6.2.1 AbbVie Inc
6.2.2 Adimmune Corp
6.2.3 Akshaya Bio Inc
6.2.4 Altimmune Inc
6.2.5 Antigen Express Inc
6.2.6 Beijing Minhai Biotechnology Co Ltd
6.2.7 BioCryst Pharmaceuticals Inc
6.2.8 Cadila Healthcare Ltd
6.2.9 CEL-SCI Corp
6.2.10 Cilian AG
6.2.11 Cocrystal Pharma Inc
6.2.12 ContraFect Corp
6.2.13 Curevac AG
6.2.14 EpiVax Inc
6.2.15 Etubics Corp
6.2.16 Gemmus Pharma Inc
6.2.17 Genentech Inc
6.2.18 iBio Inc
6.2.19 Inovio Pharmaceuticals Inc
6.2.20 Jiangsu Kanion Pharmaceutical Co Ltd
6.2.21 Johnson & Johnson
6.2.22 Kineta Inc
6.2.23 Kyowa Hakko Kirin Co Ltd
6.2.24 Lakewood-Amedex Inc
6.2.25 Medicago Inc
6.2.26 MedImmune LLC
6.2.27 Microbiotix Inc
6.2.28 Mucosis BV
6.2.29 NanoViricides Inc
6.2.30 NewLink Genetics Corp
6.2.31 Novavax Inc
6.2.32 OPKO Health Inc
6.2.33 PeptiDream Inc
6.2.34 Recce Ltd
6.2.35 Sanofi
6.2.36 Sanofi Pasteur SA
6.2.37 Sarepta Therapeutics Inc
6.2.38 SK Chemicals Co Ltd
6.2.39 Takeda Pharmaceutical Company Ltd
6.2.40 TechnoVax Inc
6.2.41 Touchlight Genetics Ltd
6.2.42 Vaccibody AS
6.2.43 Vaxart Inc
6.2.44 Vironova AB
6.2.45 Visterra Inc

7 Dormant Projects
7.1 Influenza A Virus, H5N1 Subtype Infections
7.2 Influenza A Virus, H1N1 Subtype Infections

8 Discontinued Products
8.1 Influenza A Virus, H5N1 Subtype Infections
8.2 Influenza A Virus, H1N1 Subtype Infections

9 Product Development Milestones
9.1 Influenza A Virus, H5N1 Subtype Infections
9.1.1 Featured News & Press Releases
9.2 Influenza A Virus, H1N1 Subtype Infections
9.2.1 Featured News & Press Releases

10 Appendix
10.1 Methodology10.2 Coverage
10.3 Secondary Research
10.4 Primary Research
10.5 Expert Panel Validation
10.6 Contact Us
10.7 Disclaimer

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +